Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE-4: Orforglipron vs Insulin Glargine in Type 2 Diabetes with Obesity/Overweight at High Cardiovascular Risk
2022-502833-25-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of orforglipron in type 2 diabetes mellitus (T2DM), obesity, Overweight and 2 more (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to first occurrence of MACE-4. Started Aug 2023; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweightcardiac morbiditychronic kidney disease (CKD)
Beyond the preview
Go deeper on 2022-502833-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502833-25-00.